Market Overview

NuVasive to Release $62.5M from Escrow Following Appeals Court Win

Share:
Related NUVA
NuVasive Focused On Surgeon Support And Showcasing Industry-Leading Products At North American Spine Society 29th Annual Meeting
Benzinga's Top Downgrades
The Top Mid-Cap Stocks To Buy This Week (Seeking Alpha)

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today the release of $62.5 million from a restricted escrow account in relation to NuVasive's trademark dispute regarding the NeuroVision(R) trade name.

Posted-In: News Legal

 

Related Articles (NUVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters